Literature DB >> 28360184

Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force.

Aikaterini Hatziioannou1, Themis Alissafi1, Panayotis Verginis2.   

Abstract

Important conceptual advances in tumor immunology over the last years have shifted the paradigm from focusing on the malignant cell to the importance of host immune components in the design of successful immunotherapies. The immune system, through sophisticated innate and adaptive immune surveillance mechanisms, inhibits the growth and establishment of tumors. However, despite immune surveillance, tumors still escape and grow, mainly as a result of endowed tumor-induced immunosuppressive circuits. Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are the major components of these regulatory networks that facilitate tumor immune escape and significantly compromise the efficacy of current immunotherapies. A better understanding of the induction, function, and expansion of these powerful regulatory compartments represents a major challenge on the clinical benefit of current treatments and may foster the design of novel cancer immunotherapies. © Society for Leukocyte Biology.

Entities:  

Keywords:  immune evasion; tolerogenic mechanisms; tumor immunophenotype; tumor microenvironment

Mesh:

Year:  2017        PMID: 28360184     DOI: 10.1189/jlb.5VMR1116-493R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  14 in total

1.  Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.

Authors:  Themis Alissafi; Aikaterini Hatzioannou; Konstantinos Mintzas; Roza Maria Barouni; Aggelos Banos; Sundary Sormendi; Alexandros Polyzos; Maria Xilouri; Ben Wielockx; Helen Gogas; Panayotis Verginis
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

2.  Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.

Authors:  Themis Alissafi; Panayotis Verginis; Maria Grigoriou; Aggelos Banos; Aikaterini Hatzioannou; Andreas Kloetgen; Panagiotis Kouzis; Despoina Aggouraki; Roubini Zakopoulou; Giorgos Bamias; Eva Kassi; Dimitrios Mavroudis; Aristotelis Bamias; Dimitrios T Boumpas; Aristotelis Tsirigos; Helen Gogas
Journal:  Cancer Immunol Res       Date:  2021-04-05       Impact factor: 11.151

Review 3.  Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy.

Authors:  Hiroyuki Horiguchi; Tyler J Loftus; Russell B Hawkins; Steven L Raymond; Julie A Stortz; McKenzie K Hollen; Brett P Weiss; Elizabeth S Miller; Azra Bihorac; Shawn D Larson; Alicia M Mohr; Scott C Brakenridge; Hironori Tsujimoto; Hideki Ueno; Frederick A Moore; Lyle L Moldawer; Philip A Efron
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

4.  Nano-Pulse Stimulation for the Treatment of Pancreatic Cancer and the Changes in Immune Profile.

Authors:  Siqi Guo; Niculina I Burcus; James Hornef; Yu Jing; Chunqi Jiang; Richard Heller; Stephen J Beebe
Journal:  Cancers (Basel)       Date:  2018-06-27       Impact factor: 6.639

Review 5.  Myeloid-Derived Suppressor Cells in Sepsis.

Authors:  Irene T Schrijver; Charlotte Théroude; Thierry Roger
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

Review 6.  Ping-Pong-Tumor and Host in Pancreatic Cancer Progression.

Authors:  Wei Mu; Zhe Wang; Margot Zöller
Journal:  Front Oncol       Date:  2019-12-16       Impact factor: 6.244

7.  AMP-activated protein kinase alpha1 promotes tumor development via FOXP3 elevation in tumor-infiltrating Treg cells.

Authors:  Junqing An; Ye Ding; Changjiang Yu; Jian Li; Shaojin You; Zhixue Liu; Ping Song; Ming-Hui Zou
Journal:  iScience       Date:  2021-12-04

Review 8.  Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle.

Authors:  Aikaterini Hatzioannou; Athina Boumpas; Miranta Papadopoulou; Iosif Papafragkos; Athina Varveri; Themis Alissafi; Panayotis Verginis
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

9.  Japanese Kampo Medicine Juzentaihoto Enhances Antitumor Immunity in CD1d-/- Mice Lacking NKT Cells.

Authors:  Shun Takaku; Masumi Shimizu; Hidemi Takahashi
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

Review 10.  Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.

Authors:  Alexander J Stephens; Nicola A Burgess-Brown; Shisong Jiang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.